Analyst
Guggenheim
Equibles does not estimate personal net worth.
Yatin Suneha is recorded as Analyst at Guggenheim. Yatin Suneha has spoken on 6 earnings calls and 2 other investor events across 8 companies, most recently for Argenx SE on October 22, 2026. Those appearances were for Argenx SE (ARGX), Sionna Therapeutics, Inc. (SION), Phathom Pharmaceuticals, Inc. (PHAT), Praxis Precision Medicines, Inc. (PRAX), Acadia Pharmaceuticals Inc (ACAD) and 3 other companies. The companies whose calls Yatin Suneha spoke on are classified in the Healthcare sector.
“Maybe just a few on FB102. could you just talk about the competitiveness of the data that you have generated internally in celiac relative to the other approaches?”
“Joining me are Mike Clunan, our President and Chief Executive Officer, and Charlotte McKee, our Chief Medical Officer. Also joining us for the Q&A session is Elena Ridloff, our Chief Financial Officer.”
“Steve, the friction that you are articulating I mean is this something you are seeing mostly with the new practice or new physicians that are coming on or is it mostly across the board even with the older physicians or all the practices and two I mean you guys have been very good in terms of you know cutting the cost…”
“Just a quick one on the reexamination process happening in Europe. Could you just talk about where you are? What do you expect to learn from the process there on phenotype?”
Guggenheim
Analyst
Transcript header (unverified)
ARGX
Biotechnology · Healthcare
IMVT
Biotechnology · Healthcare
